Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion Criteria: Acute pyelonephritis without severity symptoms with a positive urine culture for ESBL-producing E. coli (cefoxitin-sensitive); antibiotic treatment should have been prescribed before inclusion for the empirical treatment of pyelonephritis, providing it is not active in vitro against ESBL-producing E. coli strain.~* Presenting at least a functional sign of urinary infection (dysuria, cloudy urine, pain on urination, pelvic or lumbar pain)~* Temperature \>38 ° or \< 36° during the infectious episode~* Imaging of the urinary ways realized within (echography) 72 hours preceding the inclusion.~Exclusion Criteria:~* Pregnant women~* β-lactam allergy;~* antimicrobial therapy active in vitro against ESBL-producing E.coli pyelonephritis instituted prior to enrolment;~* life expectancy \<30 days;~* creatinine clearance \<30 ml/min;~* patient under guardianship or without healthcare coverage.~* Sign of sepsis severe or septic shock~* Major cognitive confusions~* Patients having refused to give her consent form in writing~* Not membership in a national insurance scheme or in the Universal Health Coverage (CMU).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cefoxitin (Type: EXPERIMENTAL): this study is centered on women with pyelonephritis without severity symptoms due to ESBL-producing E. coli.

Based on this trial design, predict the completion outcome and termination type (if applicable).